{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:35:42Z","timestamp":1783182942197,"version":"3.54.6"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12328-021-01515-2","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T14:02:48Z","timestamp":1630936968000},"page":"1711-1717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["TAFRO syndrome complicated by porto-sinusoidal vascular liver disease with portal hypertension: a case report"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2213-3918","authenticated-orcid":false,"given":"Manabu","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Temmoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Yashio-Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kobashi","family":"Ryoichiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Waragai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erina","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Kiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumichi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4331-0634","authenticated-orcid":false,"given":"Hiromasa","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"1515_CR1","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1002\/hep.30132","volume":"68","author":"V Hernandez-Gea","year":"2018","unstructured":"Hernandez-Gea V, Baiges A, Turon F, et al. Idiopathic portal hypertension. Hepatology. 2018;68:2413\u201323.","journal-title":"Hepatology"},{"key":"1515_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S2468-1253(19)30047-0","volume":"4","author":"A De Gottardi","year":"2019","unstructured":"De Gottardi A, Rautou PE, Schouten J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol. 2019;4:399\u2013411.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1515_CR3","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/j.1365-2036.2012.05112.x","volume":"35","author":"JN Schouten","year":"2012","unstructured":"Schouten JN, Nevens F, Hansen B, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther. 2012;35:1424\u201333.","journal-title":"Aliment Pharmacol Ther"},{"key":"1515_CR4","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1002\/hep.26904","volume":"59","author":"S Siramolpiwat","year":"2014","unstructured":"Siramolpiwat S, Seijo S, Miquel R, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatology. 2014;59:2276\u201385.","journal-title":"Hepatology"},{"key":"1515_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.critrevonc.2018.05.015","volume":"128","author":"S Paydas","year":"2018","unstructured":"Paydas S. Tafro syndrome: critical review for clinicians and pathologists. Crit Rev Oncol Hematol. 2018;128:88\u201395.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1515_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/ajh.25554","volume":"94","author":"S Fujimoto","year":"2019","unstructured":"Fujimoto S, Sakai T, Kawabata H, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019;94:975\u201383.","journal-title":"Am J Hematol"},{"key":"1515_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12185-019-02780-1","volume":"111","author":"Y Masaki","year":"2020","unstructured":"Masaki Y, Kawabata H, Takai K, et al. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020;111:155\u20138.","journal-title":"Int J Hematol"},{"key":"1515_CR8","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/0284186X.2017.1404637","volume":"57","author":"AL Pinto","year":"2018","unstructured":"Pinto AL, Gomes M, Cipriano MA, et al. Non-cirrhotic portal hypertension associated with multicentric Castleman\u2019s disease: a case report. Acta Oncol. 2018;57:703\u20135.","journal-title":"Acta Oncol"},{"key":"1515_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/0284186X.2019.1574980","volume":"58","author":"DM Kobrin","year":"2019","unstructured":"Kobrin DM, Pinto AL, Parente ST, et al. Letter to the editor regarding \u201cNon-cirrhotic portal hypertension associated with multicentric Castleman\u2019s disease: a case report.\u201d Acta Oncol. 2019;58:515\u20137.","journal-title":"Acta Oncol"},{"key":"1515_CR10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.24242","volume":"91","author":"N Iwaki","year":"2016","unstructured":"Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91:220\u20136.","journal-title":"Am J Hematol"},{"key":"1515_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1177\/0961203317747719","volume":"27","author":"SS Ahn","year":"2018","unstructured":"Ahn SS, Park Y, Lee DD, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein can reflect systemic lupus erythematosus activity. Lupus. 2018;27:771\u20139.","journal-title":"Lupus"},{"key":"1515_CR12","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ekir.2020.05.004","volume":"5","author":"H Mizuno","year":"2020","unstructured":"Mizuno H, Sawa N, Watanabe S, et al. The clinical and histopathological feature of renal manifestation of TAFRO syndrome. Kidney Int Rep. 2020;5:1172\u20139.","journal-title":"Kidney Int Rep"},{"key":"1515_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.hoc.2017.09.009","volume":"32","author":"T Igawa","year":"2018","unstructured":"Igawa T, Sato Y. TAFRO syndrome. Hematol Oncol Clin North Am. 2018;32:107\u201318.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1515_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.7326\/L20-1051","volume":"174","author":"M Killian","year":"2021","unstructured":"Killian M, Viel S, Chalayer E, et al. JAK1\/2 inhibition in severe TAFRO syndrome: a case report. Ann Intern Med. 2021;174:719\u201321.","journal-title":"Ann Intern Med"},{"key":"1515_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/gutjnl-2015-309600","volume":"66","author":"S Klein","year":"2017","unstructured":"Klein S, Rick J, Lehmann J, et al. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. Gut. 2017;66:145\u201355.","journal-title":"Gut"},{"key":"1515_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s10620-005-1601-5","volume":"50","author":"A Kiyuna","year":"2005","unstructured":"Kiyuna A, Sunagawa T, Hokama A, et al. Nodular regenerative hyperplasia of the liver and Castleman\u2019s disease: potential role of interleukin-6. Dig Dis Sci. 2005;50:314\u20136.","journal-title":"Dig Dis Sci"},{"key":"1515_CR17","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0344-0338(11)80662-X","volume":"191","author":"T Molina","year":"1995","unstructured":"Molina T, Delmer A, Le Tourneau A, et al. Hepatic lesions of vascular origin in multicentric Castleman\u2019s disease, plasma cell type: report of one case with peliosis hepatis and another with perisinusoidal fibrosis and nodular regenerative hyperplasia. Pathol Res Pract. 1995;191:1159\u201364.","journal-title":"Pathol Res Pract"},{"key":"1515_CR18","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1093\/emboj\/17.19.5588","volume":"17","author":"D Maione","year":"1998","unstructured":"Maione D, Di Carlo E, Li W, et al. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J. 1998;17:5588\u201397.","journal-title":"EMBO J"},{"key":"1515_CR19","first-page":"31629","volume":"S1542\u20133565","author":"K Woran","year":"2020","unstructured":"Woran K, Semmler G, Jachs M, et al. Clinical course of porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension. Clin Gastroenterol Hepatol. 2020;S1542\u20133565:31629\u201333.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1515_CR20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s12185-016-1979-1","volume":"103","author":"Y Masaki","year":"2016","unstructured":"Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103:686\u201392.","journal-title":"Int J Hematol"},{"key":"1515_CR21","doi-asserted-by":"publisher","first-page":"e11045","DOI":"10.1097\/MD.0000000000011045","volume":"97","author":"T Shirai","year":"2018","unstructured":"Shirai T, Onishi A, Waki D, et al. Successful treatment with tacrolimus in TAFRO syndrome: two case reports and literature review. Medicine (Baltimore). 2018;97:e11045.","journal-title":"Medicine (Baltimore)"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01515-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-021-01515-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01515-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T16:10:25Z","timestamp":1635610225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-021-01515-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1007\/s12328-021-01515-2","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"assertion":[{"value":"16 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Manabu Hayashi, Jun Wada, Masashi Fujita, Tomoyuki Asano, Naoki Matsuoka, Yuya Fujita, Jumpei Temmoku, Haruki Matsumoto, Makiko Yashio-Furuya, Shuzo Sato, Hiroko Kobayashi, Hiroshi Watanabe, Kobashi Ryoichiro, Yuichi Waragai, Erina Suzuki, Yuichiro Kiko, Kazumichi Abe, Atsushi Takahashi, Tomoyuki Masuda, Yuko Hashimoto, Kiyoshi Migita, and Hiromasa Ohira declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}